SCHEMBL6162573

SCHEMBL6162573

Cc1cc(C#N)ccc1OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.47
MRGPRX4 Q96LA9 1/20 0.42
SSTR4 P31391 1/20 0.41
TRPV4 Q9HBA0 2/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP2A6 P11509 1/20 0.39
LRRK2 Q5S007 1/20 0.39
TBXA2R P21731 2/20 0.37
ESRRA P11474 1/20 0.36
SLC6A4 P31645 2/20 0.36
KCNH2 Q12809 2/20 0.36
SLC6A3 Q01959 1/20 0.36
KIF11 P52732 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
HTR2A P28223 1/20 0.35
S1PR1 P21453 1/20 0.35
NCEH1 Q6PIU2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2637250 0.84 AR (0.43) ARMRGPRX4SSTR4ALDH1A1CYP2A6
SCHEMBL25044876 0.82 MRGPRX4 (0.40) ARMRGPRX4SSTR4TRPV4ALDH1A1
SCHEMBL14805912 0.81 AR (0.55) ARMRGPRX4TRPV4ESRRASLC6A4
SCHEMBL6165493 0.80 AR (0.40) ARTRPV4ALDH1A1CYP2A6TBXA2R
SCHEMBL13019869 0.80 AR (0.55) ARTRPV4ALDH1A1LRRK2SLC6A4
SCHEMBL17654529 0.79 TRPV4 (0.55) ARMRGPRX4SSTR4TRPV4ESRRA
SCHEMBL931494 0.79 AR (0.60) ARMRGPRX4ALDH1A1CYP2A6LRRK2
SCHEMBL14805812 0.76 TRPV4 (0.42) ARTRPV4SLC6A4KCNH2SLC6A3
SCHEMBL6165080 0.76 SLC6A4 (0.42) ARTRPV4TBXA2RSLC6A4KCNH2
SCHEMBL9700152 0.76 FBP1 (0.54) MRGPRX4SSTR4TRPV4TBXA2RPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298032-A1 SPHINGOSINE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-10-19 US disclosed
US-20130079323-A1 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2013-03-28 US disclosed
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298032-A1 SPHINGOSINE KINASE INHIBITORS SPHK1, SPHK2, S1PR2 AR 1199/4885MRGPRX4 1068/4885SSTR4 1651/4885
US-20130079323-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B AR 2395/4885MRGPRX4 4276/4885SSTR4 4532/4885
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI AR 2202/4885MRGPRX4 2267/4885SSTR4 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.